/STVN
STVN Stock - Stevanato Group S.p.A.
Healthcare|Medical - Instruments & SuppliesNYSE
$20.53+0.05%
+$0.01 (+0.05%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).84
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.9%upside
Target: $24.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.32 – $20.74
TARGET (TP)$24.00
STOP LOSS$18.89
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$28.00
52W Low$17.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.10B | $1.09B | $983.68M | $843.92M | $662.04M |
| Gross Profit | $302.32M | $339.89M | $319.80M | $265.40M | $194.18M |
| Gross Margin | 27.4% | 31.3% | 32.5% | 31.4% | 29.3% |
| Operating Income | $161.14M | $200.72M | $192.43M | $162.22M | $103.11M |
| Net Income | $117.78M | $145.63M | $142.85M | $134.32M | $78.51M |
| Net Margin | 10.7% | 13.4% | 14.5% | 15.9% | 11.9% |
| EPS | $0.43 | $0.55 | $0.53 | $0.53 | $0.28 |
Company Overview
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
43%
Hold / Neutral
4
57%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
3 Bullish4 Neutral/Bearish
Price Targets
$29
Average Target
↑ 38.8% Upside
Now
$23
Low
$29
Average
$34
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Equal Weight | $24 |
| December 13th 2024 | Wolfe Research | Initiation | Outperform | $28 |
| December 3rd 2024 | Morgan Stanley | Resumed | Equal Weight | $23 |
| April 22nd 2024 | Exane BNP Paribas | Initiation | Outperform | - |
| November 1st 2023 | Jefferies | Downgrade | Hold | $29← $39 |
| September 26th 2023 | Stephens | Initiation | Overweight | $33 |
| September 19th 2023 | CJS Securities | Initiation | Market Outperform | - |
| August 24th 2023 | Morgan Stanley | Downgrade | Equal Weight | $34 |
Earnings History & Surprises
STVNBeat Rate
50%
Last 18 quarters
Avg Surprise
+2.5%
EPS vs Estimate
Beats / Misses
9/6
3 met exactly
Latest EPS
$0.16
Q4 2025
EPS Surprise History
Q1 24
-5.3%
$0.20vs$0.21
Q2 24
-27.3%
$0.09vs$0.12
Q3 24
-10.0%
$0.10vs$0.11
Q4 24
-7.7%
$0.13vs$0.14
Q1 25
0.0%
$0.20vs$0.20
Q2 25
+10.0%
$0.11vs$0.10
Q3 25
+9.1%
$0.12vs$0.11
Q4 25
+14.3%
$0.16vs$0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $0.19 | — | — | — |
Q1 2026 | Mar 5, 2026 | $0.19 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.14 | $0.16 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.11 | $0.12 | +9.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.10 | $0.11 | +10.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $0.20 | $0.20 | 0.0% | = MET |
Q4 2024 | Nov 5, 2024 | $0.14 | $0.13 | -7.7% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $0.11 | $0.10 | -10.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.12 | $0.09 | -27.3% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $0.21 | $0.20 | -5.3% | ✗ MISS |
Q4 2023 | Oct 31, 2023 | $0.16 | $0.16 | 0.0% | = MET |
Q3 2023 | Jul 28, 2023 | $0.14 | $0.15 | +7.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.13 | $0.12 | -8.3% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $0.17 | $0.19 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.13 | $0.14 | +7.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.12 | $0.12 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $0.10 | $0.11 | +10.0% | ✓ BEAT |
Q1 2022 | Mar 8, 2022 | $0.11 | $0.14 | +30.0% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $0.11 | $0.12 | +9.1% | ✓ BEAT |
Q3 2021 | Aug 19, 2021 | $0.18 | $0.16 | -6.7% | ✗ MISS |
Latest News
Morgan Stanley Maintains Equal-Weight on Stevanato Group, Lowers Price Target to $24
➖ NeutralBenzinga•Dec 2, 2025, 05:56 PM
Morgan Stanley Maintains Equal-Weight on Stevanato Group, Raises Price Target to $26
📈 PositiveBenzinga•Nov 11, 2025, 04:56 PM
STVN stock has given up its prior gain. Stevanato Group shares were trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 03:10 PM
CORRECTION: Stevanato Group Affirms FY2025 GAAP EPS Guidance of $0.54-$0.59 vs $0.61 Est
📉 NegativeBenzinga•Nov 6, 2025, 03:00 PM
CORRECTION: Stevanato Group Affirms FY2025 Adj EPS Guidance of $0.53-$0.57 vs $0.61 Est; Affirms FY2025 Sales Guidance of $1.238B-$1.270B vs $1.360B Est
📉 NegativeBenzinga•Nov 6, 2025, 03:00 PM
Stevanato Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 01:39 PM
Stevanato Group Raises FY2025 GAAP EPS Guidance from $0.54-$0.59 to $0.56-$0.61 vs $0.61 Est
➖ NeutralBenzinga•Nov 6, 2025, 11:43 AM
Stevanato Group Raises FY2025 Adj EPS Guidance from $0.53-$0.57 to $0.58-$0.63 vs $0.61 Est; Raises FY2025 Sales Guidance from $1.238B-$1.270B to $1.391B vs $1.360B Est
📈 PositiveBenzinga•Nov 6, 2025, 11:43 AM
Stevanato Gr Q3 Adj. EPS $0.16 Beats $0.14 Estimate, Sales $354.507M Beat $335.830M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 11:31 AM
Stevanato Group Expands German Facility To Boost Drug Delivery Device Production And Strengthen Global Pharma Supply Chain
📈 PositiveBenzinga•Oct 21, 2025, 10:36 AM
Frequently Asked Questions about STVN
What is STVN's current stock price?
Stevanato Group S.p.A. (STVN) is currently trading at $20.53 per share. The stock has moved +0.05% today.
What is the analyst price target for STVN?
The average analyst price target for STVN is $24.00, based on 1 analyst.
What sector is Stevanato Group S.p.A. in?
Stevanato Group S.p.A. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NYSE exchange.
What is STVN's market cap?
Stevanato Group S.p.A. has a market capitalization of $5.60 billion, making it a mid-cap company.
Does STVN pay dividends?
No, Stevanato Group S.p.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATR
AptarGroup, Inc.
$121.39
Mkt Cap: $8.0B
AVTR
Avantor, Inc.
$11.27
Mkt Cap: $7.7B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
BLCO
Bausch + Lomb Corporation
$16.98
Mkt Cap: $6.0B
BTSG
BrightSpring Health Services, Inc. Common Stock
$37.49
Mkt Cap: $6.8B
CHE
Chemed Corporation
$435.33
Mkt Cap: $6.4B
MASI
Masimo Corporation
$134.04
Mkt Cap: $7.2B
MMSI
Merit Medical Systems, Inc.
$87.70
Mkt Cap: $5.2B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
Explore stocks similar to STVN for comparison